AMGN:NSD-Amgen Inc (USD)

COMMON STOCK | Drug Manufacturers-General | NSD

Last Closing Price

USD 255.05

Change

-3.73 (-1.44)%

Market Cap

USD 149.01B

Volume

3.29M

Average Target Price

USD 262.27 (+2.83%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; and Datos Health. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-22 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AZN AstraZeneca PLC

-0.40 (-0.75%)

USD139.89B 43.62 17.51
SNY Sanofi

-0.40 (-0.76%)

USD129.31B 8.89 7.68
GILD Gilead Sciences, Inc

-1.15 (-1.72%)

USD84.09B 681.53 25.90
CELG Celgene Corporation

N/A

USD77.04B 13.33 10.62
BIIB Biogen Inc

-10.85 (-4.02%)

USD40.80B 10.80 8.09
HZNP Horizon Therapeutics Public Li..

+0.60 (+0.64%)

USD20.41B 50.31 26.74
GRFS Grifols, S.A

+0.47 (+2.59%)

USD16.27B 33.80 16.87
GWPH GW Pharmaceuticals plc

+0.01 (+0.00%)

USD6.70B 91.14 84.16

ETFs Containing AMGN

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

-0.16 (-0.09%)

USD0.50B
EMWE:F BNP Paribas Easy MSCI Wor.. 0.00 % 0.00 %

+0.08 (+0.51%)

N/A
CIND:LSE iShares VII PLC - iShares.. 0.00 % 0.33 %

+1.16 (+0.30%)

USD0.82B
IHCU:LSE iShares S&P 500 Health Ca.. 0.00 % 0.15 %

+5.88 (+0.88%)

USD1.69B
IUHC:LSE iShares S&P 500 Health Ca.. 0.00 % 0.15 %

+0.02 (+0.24%)

USD1.45B
SBUY:LSE Invesco Global Buyback Ac.. 0.00 % 0.39 %

+37.50 (+1.08%)

USD0.05B
UC46:LSE UBS(Lux)Fund Solutions &#.. 0.00 % 0.28 %

+142.00 (+1.12%)

USD1.71B
VMVL:LSE Vanguard Global Minimum V.. 0.00 % 0.00 %

N/A

USD0.05B
XSHC:LSE Xtrackers MSCI USA Health.. 0.00 % 0.12 %

+38.50 (+1.06%)

USD0.49B
XUHC:LSE Xtrackers (IE) Plc - Xtra.. 0.00 % 0.12 %

+0.17 (+0.34%)

USD0.49B
BUYB:PA Invesco Global Buyback Ac.. 0.00 % 0.39 %

+0.24 (+0.59%)

USD0.05B
EKLD:PA BNP Paribas Easy MSCI USA.. 0.00 % 0.00 %

+0.07 (+0.43%)

USD0.31B
EKUS:PA BNP Paribas Easy - MSCI U.. 0.00 % 0.00 %

+0.10 (+0.63%)

USD0.37B
3SUR:F iShares IV Public Limited.. 0.00 % 0.23 %

+1.80 (+0.12%)

N/A
BBCK:F Invesco Global Buyback Ac.. 0.00 % 0.39 %

-0.12 (-0.29%)

USD0.05B
EXI3:F iShares Dow Jones Industr.. 0.00 % 0.51 %

+0.15 (+0.05%)

USD6,289.39B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.13 (+2.63%)

USD0.34B
MJMT:F Amundi Index Solutions - .. 0.00 % 0.00 %

+0.91 (+1.07%)

USD0.39B
SXRU:F iShares VII PLC - iShares.. 0.00 % 0.33 %

+0.05 (+0.02%)

USD0.82B
UIMP:F UBS(Lux)Fund Solutions &#.. 0.00 % 0.28 %

+0.70 (+0.48%)

USD1.71B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.12 (+2.11%)

USD0.35B
BBCK:XETRA Invesco Global Buyback Ac.. 0.00 % 0.39 %

+0.24 (+0.59%)

USD0.05B
EKLD:XETRA BNP Paribas Easy MSCI USA.. 0.00 % 0.00 %

+0.08 (+0.47%)

USD0.31B
EXI3:XETRA iShares Dow Jones Industr.. 0.00 % 0.51 %

+1.55 (+0.55%)

USD6,289.39B
GNAR:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

+0.49 (+0.64%)

USD2.84B
MJMT:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

+1.16 (+1.37%)

USD0.41B
SXRU:XETRA iShares VII PLC - iShares.. 0.00 % 0.33 %

+1.65 (+0.51%)

USD0.82B
UEFY:XETRA UBS ETF - SBI Foreign AAA.. 0.00 % 0.20 %

N/A

USD0.17B
UET1:XETRA UBS(Lux)Fund Solutions &#.. 0.00 % 0.33 %

+0.09 (+0.39%)

USD0.18B
UIMP:XETRA UBS(Lux)Fund Solutions &#.. 0.00 % 0.28 %

+1.00 (+0.68%)

USD1.72B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.13 (+1.87%)

USD0.03B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.12 (+1.80%)

USD0.34B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-0.03 (-0.03%)

USD0.20B
RSP Invesco S&P 500 Equal Wei.. 0.00 % 0.20 %

-0.93 (-0.63%)

USD24.27B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

+0.01 (+0.06%)

USD0.01B
BLV Vanguard Long-Term Bond I.. 0.00 % 0.05 %

+0.24 (+0.24%)

USD10.39B
CURE Direxion Daily Healthcare.. 0.00 % 1.01 %

-1.19 (-1.21%)

USD0.13B
DDM ProShares Ultra Dow30 0.00 % 0.95 %

-1.28 (-1.82%)

USD0.44B
DIA SPDR Dow Jones Industrial.. 0.00 % 0.16 %

-3.18 (-0.93%)

USD25.79B
DJD Invesco Dow Jones Industr.. 0.00 % 0.07 %

-0.65 (-1.47%)

USD0.13B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.55 %

-0.28 (-0.17%)

USD1.91B
HEA:CA Horizons Enhanced Income .. 0.00 % 0.65 %

N/A

USD0.03B
IBB iShares Nasdaq Biotechnol.. 0.00 % 0.46 %

+0.09 (+0.06%)

USD10.74B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.02 %

+2.56 (+3.53%)

USD0.51B
LNGR Global X Aging Population.. 0.00 % 0.50 %

N/A

USD0.04B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.58 %

+0.49 (+0.65%)

USD0.28B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

-0.85 (-1.06%)

USD0.36B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

+0.05 (+0.67%)

USD1.42M
SDG iShares MSCI Global Impac.. 0.00 % 0.49 %

+0.15 (+0.15%)

USD0.43B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

+0.05 (+0.67%)

USD1.42M
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

-0.59 (-0.66%)

USD0.12B
RYH Invesco S&P 500 Equal Wei.. 0.00 % 0.40 %

-0.31 (-0.11%)

USD0.78B
SCHD Schwab U.S. Dividend Equi.. 0.00 % 0.06 %

-0.95 (-1.26%)

USD21.26B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
UDOW ProShares UltraPro Dow30 0.00 % 0.95 %

-4.03 (-2.85%)

USD0.85B
XLV Health Care Select Sector.. 0.00 % 0.12 %

-0.55 (-0.45%)

USD24.05B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
ZDJ:CA BMO Dow Jones Industrial .. 0.00 % 0.23 %

-0.52 (-0.95%)

USD0.27B
ZWA:CA BMO Covered Call Dow Jone.. 0.00 % 0.65 %

-0.19 (-0.72%)

USD0.22B
PRP:CA Purpose Conservative Inco.. 0.00 % 0.71 %

-0.03 (-0.14%)

USD2.08M
EDOW First Trust Dow 30 Equal .. 0.00 % 0.50 %

-0.33 (-1.08%)

USD0.08B
HONR InsightShares Patriotic E.. 0.00 % 0.65 %

N/A

USD1.34M
VMVL:XETRA Vanguard Global Minimum V.. 0.00 % 0.00 %

N/A

USD0.05B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.93% 63% D 57% F
Dividend Return 0.77% 33% F 54% F
Total Return 11.70% 63% D 58% F
Trailing 12 Months  
Capital Gain 9.70% 75% C 21% F
Dividend Return 2.82% 60% D- 46% F
Total Return 12.53% 75% C 21% F
Trailing 5 Years  
Capital Gain 56.29% 63% D 55% F
Dividend Return 16.45% 80% B- 62% D-
Total Return 72.74% 63% D 58% F
Average Annual (5 Year Horizon)  
Capital Gain 10.98% 75% C 59% F
Dividend Return 2.96% 40% F 72% C-
Total Return 13.94% 75% C 62% D-
Risk Return Profile  
Volatility (Standard Deviation) 12.06% 75% C 88% B+
Risk Adjusted Return 115.57% 88% B+ 96% A
Market Capitalization 149.01B 100% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 21.02 75% C 48% F
Price/Book Ratio 15.66 13% F 10% F
Price / Cash Flow Ratio 14.20 63% D 31% F
EV/EBITDA 13.06 75% C 63% D
Management Effectiveness  
Return on Equity 76.14% 100% A+ 99% A+
Return on Invested Capital 20.18% 100% A+ 91% A-
Return on Assets 9.51% 75% C 94% A
Debt to Equity Ratio 349.61% 14% F 4% F
Technical Ratios  
Short Ratio 3.65 25% F 31% F
Short Percent 1.98% 75% C 66% D
Beta 0.74 38% F 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.